Vivus (and other obesity stocks) slims down after Qsymia flop
This article was originally published in Scrip
Executive Summary
With Qsymia (topiramate and phentermine) generating just $2 million in sales between its September launch and the end of 2012, Vivus' stock has fallen to nearly one-third of the $29 price it achieved after US FDA approval of its weight loss drug seven months ago.